FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

ı	OMB APPROVAL								
	OMB Number:	3235-028							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

1. Name and Address of Reporting Person*  BOGER KENNETH S							2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]									tionship of Reporting all applicable) Director Officer (give title below)		10% Ov Other (s below)	vner			
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED							3. Date of Earliest Transaction (Month/Day/Year) 08/03/2009									SVP & General Counsel						
130 WAVERLY STREET  (Street)  CAMBRIDGE MA 02139  (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)								Indivi ne) X	·							
(0.5)	(0			lon-Deri	vativ	- Sec	curit	tios Ar	auiro	d D	isnosad o	of or Re	neficia	llv (	Owned							
1. Title of Security (Instr. 3)					ction ay/Year)	2A. Deemed Execution Date,		ned n Date,	3. Transaction		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an		(A) or	5. Amount of Securities Beneficially Owned Followin		nt of es ally Following	6. Ownership Form: Direct (D) or Indirec (I) (Instr. 4)		Ownership			
									Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Common	Stock			08/03/	8/03/2009				М		17,820	Α	\$18.7	75 1		3,677		D				
Common Stock 08/03/						)09			М		3,024	A	\$17.1	.16 110		6,701		D				
Common Stock 08/03/20						)09			S <sup>(1)</sup>		20,844	D	\$36.02	(3)(4)	95,857			D				
Common Stock															4,364			I	401(k)			
			Table II								posed of, converti			y O\	wned							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Dee Execution if any (Month/		4. Transa Code ( 8)				6. Date Exerr Expiration D (Month/Day/		ate	of Securi Underlyir	ng e Security	De Se	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Own Forn Dire or In (I) (Ii	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amount or Number of Shares									
Stock Options	\$18.75	08/03/2009			M	М		17,820	(2	2)	09/23/2011	Common Stock	17,820	20 \$0 0		0	D					
Stock	\$17.16	08/03/2000			М			3.024	(2	2)	07/19/2015	Common	2.024		90	0		D				

## **Explanation of Responses:**

- 1. Transaction made pursuant to Mr. Boger's company approved trading plan established under Rule 10b5-1.
- 3. Open market sales reported on this line occurred at a weighted average price of \$36.02 (range \$36.00 to \$36.26).
- 4. Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

## Remarks:

Valerie L. Andrews, Attorney-

08/04/2009

In-Fact

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.